Sun Trumps Canadian Biotech To Acquire US Eye Care Firm
This article was originally published in Scrip
Sun Pharmaceutical Industries has snapped up the US ophthalmology firm InSite Vision Inc as it sets its sights on a play in the US branded eye care space, edging out previous bidder and Canadian biotech QLT Inc.
You may also be interested in...
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.